echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > "Call the board" Pfizer? Moderna's new crown vaccine is effective and stable?

    "Call the board" Pfizer? Moderna's new crown vaccine is effective and stable?

    • Last Update: 2021-01-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    New crown vaccine research and development and then spread good news! Following Pfizer's announcement last week that the vaccine was "more than 90 percent effective," biotech company Moderna announced on November 16th local time that its experimental vaccine was 94.5 percent effective in preventing the new coronavirus, based on interim data from a late-stage clinical trial.
    Moderna says its new crown vaccine is stable for 30 days at refrigerator temperature and does not require on-site dilution, with a phase III trial vaccine that is 94.5 percent effective and is generally safe and well-resistant, with side effects including fatigue, muscle and joint pain and headaches.
    said it has millions of doses of the new crown vaccine ready and plans to apply to the U.S. in the coming weeks for emergency use of the new crown vaccine pending FDA approval.
    01 validity of the batle? Cold chain technology may seem like a 94.5 percent effective mRNA vaccine at first glance better than Pfizer's previously announced "more than 90 percent effectiveness," but the industry remains cautious about the data even if the data released by vaccine companies is positive.
    Current phase 3 trials of both vaccines are still in the process, and it is generally accepted that clinical trials often demonstrate the safety and immunogenicity of vaccines under ideal conditions, often overestimating their true protection under real conditions of routine use.
    Many industry experts have publicly stated that the vaccine effectiveness data currently published are a percentage of the reduction in the rate of disease in the vaccination group under optimal conditions compared to the unvaccinated control group, a very high percentage obtained under very specific clinical trial conditions, and that real-world conditions can skew the results.
    it is worth noting that the current mRNA vaccine technical difficulties are how to ensure product stability, and in the preservation, transportation technology there are many bottlenecks, the stability of the two mRNA vaccine issues have attracted market attention.
    the main advantage of the Moderna vaccine over Pfizer's vaccine is that it has lower requirements for ultra-cold storage and better performance in transportation and storage.
    the vaccine remains stable for 30 days at a refrigerated temperature in a standard household or medical refrigerator (2 to 8 degrees Celsius), according to Moderna.
    can remain stable for up to 6 months at a freezing temperature of -20 degrees Celsius.
    stability at room temperature for up to 12 hours.
    , Pfizer's vaccines must be shipped and stored at temperatures below -70C and for up to five days at standard refrigerated temperatures.
    means that most of the existing cold chain systems are difficult to meet the transportation needs of the vaccine.
    , WHO has warned that high requirements for cold chain storage will not be conducive to the availability of vaccines in resource-poor remote areas and developing countries.
    it is understood that in China Fosun Pharma and Haier Bio and other enterprises are in contact with enterprises in the cryogenic storage industry, to explore low-temperature storage solutions for vaccines.
    as of the time of writing, the A-share vaccine cold chain sector in the last four trading days has risen more than 4%, of which the ice wheel environment with Fosun Pharma has been a definitive cooperation in three trading days has risen 24%.
    November 11, the ice wheel environment said on the interactive platform: "In order to maintain the activity of active ingredients, some medical supplies, including vaccines, have a temperature-controlled just need."
    cooling equipment in the ice wheel environment has been used in the pharmaceutical industry for a long time, in recent years, Haizheng Pharmaceuticals, Green Leaf Pharmaceuticals, Qilu Pharmaceuticals, Kyusju Tong and other customers.
    extreme cases, some medical supplies, such as the new coronavirus mRNA vaccine, require long-term storage in environments where -70 degrees Celsius is required.
    it is understood that a business unit in the current ice wheel environment is building a company owned by Fosun Pharma -70C ultra-low temperature biocosmody storage.
    "While Pfizer vaccines have preempted the opportunity, the growing barriers to cold-chain infrastructure, funding, and so on will also create obstacles to the availability of Pfizer vaccines that are subject to refrigeration conditions and time-saving requirements, while countries that use the Moderna vaccine do not need to build the mass frozen production, storage and transportation networks needed to survive vaccines from scratch.
    , a former vaccine expert at the Shanghai CDC, said publicly in the media: "Unless Pfizer produces an improved version of thermal stability, the cold chain will have to be rebuilt."
    "02, why mRNA? Both Pfizer a week ago and Moderna today have focused their attention on the mRNA vaccine.
    traditional vaccine technology pathway is mostly inactivation, detoxification and protein recombination technology, with the rise of new technologies such as viral vector vaccine, nucleic acid vaccine (mRNA vaccine and DNA vaccine), which provides a new way of thinking for the development of new crown vaccine.
    among the many emerging vaccine technologies, mRNA vaccines have gained the favor of pharmaceutical companies around the world and become one of the main technology routes for the development of the new crown vaccine, relying on their safety, effectiveity and short research and development cycle.
    for the new coronavirus, an mRNA vaccine instructs the body's cells to produce the new coronavirus's S-tingling protein to help the immune system remember the new coronavirus.
    it is understood that, unlike traditional vaccines that introduce antigen proteins directly to stimulate the host immune response, mRNA vaccines have the advantages of short research and development cycle, good immunogenicity, good safety and high R .
    It is precisely because of the relatively convenient synthesis and production process, relatively low research and development costs, can quickly achieve capacity expansion, to meet the global supply and other qualities, mRNA vaccine has become a global vaccine competition in the higher proportion of research and development type, but also one of the well-regarded vaccine species, China, the United States, Germany, research and development teams and pharmaceutical companies are developing mRNA vaccine.
    although mRNA vaccine technology has developed rapidly in recent years, the development technology of mRNA vaccine is not very mature at present, so far, there is no precedent for approval worldwide.
    03 How is the mRNA vaccine progressing in China? When Modelna competes with Pfizer's mRNA vaccine, where are China's vaccine companies in the mRNA race? On November 10, Watson Bio announced that the first new mRNA crown vaccine (ARCoV) in China, jointly developed by the Military Medical Research Institute of the Chinese People's Liberation Army Academy of Military Sciences, Suzhou Aibo Biotech Co., Ltd. and Yunnan Watson Biotechnology Co., Ltd., is still in the first phase of clinical trials.
    June 28 this year, Watson Bio announced that it had received approval from the National Drug Administration for the new coronavirus mRNA vaccine "Drug Clinical Trial Approval."
    the announcement, the clinical trial approval is the new crown vaccine as an injection, a total of 0.125 ml / branch, 0.25 ml / branch, 0.5 ml / branch three specifications.
    As China's first new mRNA coronavirus vaccine approved to enter the clinical trial stage, the vaccine research has also been the Ministry of Science and Technology key research and development program "public safety risk prevention and control and emergency technical equipment" key special support for the Ministry of Science and Technology deployed the new crown vaccine in the five technical routes of the "nucleic acid vaccine" technology route.
    as early as June this year, the ARCoV vaccine project leader, the Military Academy of Sciences Institute of Military Medicine researcher Qin Chengfeng in an interview with the media, said that mRNA vaccine has a high technical threshold, china has never approved the mRNA vaccine into the clinic.
    with the approval of the first clinical approval of mRNA vaccine, the breakthrough of mRNA vaccine "zero" in China has been achieved, and also marks that China's mRNA vaccine has been among the forefront of the world.
    Although slightly behind in the "speed", but the industry generally believes that the domestic mRNA vaccine still has a very large advantage, first, the vaccine antigen target selection is more accurate, induced neutral antibody specificity is high, better vaccine safety;
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.